Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-23

Clinical Trial Update: An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

This is a Phase 1 ascending-dose study of PIT565 in participants with rheumatoid arthritis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PIT565 (PIT565)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 1 | Status: RECRUITING